Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.

Award Number: R44AI179385
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/21/2023
PERIOD OF PERFORMANCE END DATE: 01/31/2027

Group Awards By:

View Award Description

Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. - PROJECT SUMMARY Sjögren’s syndrome (SjS) is a highly disabling systemic autoimmune disease. Symptoms include mucosal dryness (as a result of the destruction of the epithelium of exocrine glands, mainly the salivary and lacrimal glands), pain, and fatigue. Moreover, 30-50% of patients risk systemic and potentially lethal complications. Candidate therapeutics for the disease over the past 20 years all failed to provide benefit: there is no approved immunomodulatory treatment for SjS patients. Recently, targeting the CD40/CD40L interaction, a key and well- known pathway in T-cell-mediated B-cell activation emerged as a promising therapeutic strategy for SjS in mouse models of the disease. However, prospective clinical use of anti-CD40L antibodies is highly likely to display life- threatening adverse events: these candidates are known to trigger thromboembolic events. Also, testing of current CD40 antagonists in several autoimmune diseases displayed poor results, confirming that CD40 is an extremely elusive target. Boston Immune Technologies and Therapeutics (BITT) is developing BITT-101, a uniquely efficient dominant antagonist to CD40. CD40L can easily displace antagonists raised against trimeric (active) forms of CD40; our BITT-101 binds and stabilizes the inactive dimeric form of CD40, dominantly blocking CD40-CD40L interaction, even in the presence of ligand. BITT has already completed extensive BITT-101 validation, demonstrating its dominant antagonist activity in vitro in CD40L-induced B-cell proliferation assays, and in in vivo models of GvHD. Results in this model also confirmed that BITT-101 outcompetes current CD40 antagonists, by selectively depleting active B cells, prospectively allowing for lower dosage and higher efficacy and safety. In the proposed Fast-Track project, BITT will complete pre-clinical assessment of BITT-101 to obtain relevant data for an Investigational New Drug (IND) application. BITT will confirm BITT-101 activity in primary cells from SjS patients during Phase I, which will provide proof of concept for BITT-101 use in this clinically unmet disease. Positive Phase I results will also allow advancement to IND-enabling toxicology and pharmacokinetic studies, to be conducted in Phase II. During the Phase II, BITT will also test BITT-101 production process suitability for GLP standard compliance. At the end of the SBIR project, BITT will be ready to advance BITT-101 to GMP production and clinical testing for which a combination of third-party investor funds and SBIR Phase IIb are expected to be leveraged. Successful completion of this project and initial clinical testing evidence will help to secure the already expressed interest of pharmaceutical companies with whom BITT will engage to complete late-stage clinical testing in SjS and launch BITT-101 into international markets, first for SjS and then for other auto-immune diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $990,243 )
2026	2026	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	3	6/1/2026	NON-COMPETING CONTINUATION	$990,243
														Subtotal = $990,243

Issue Date FY: 2025 ( Subtotal = $926,858 )
2025	2025	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	2	2/13/2025	EXTENSION WITH OR WITHOUT FUNDS	$926,858
2025	2023	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Allergy and Infectious Diseases Research	001	1	2/18/2025	NEW	$0
														Subtotal = $926,858

Issue Date FY: 2023 ( Subtotal = $298,049 )
2023	2023	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	1	8/21/2023	NEW	$298,049
														Subtotal = $298,049

Grand Total All Awards = $2,215,150

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.

Award Number: R44AI179385

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/21/2023

PERIOD OF PERFORMANCE END DATE: 01/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer